CANBRIDGE PHARM.DL-00001 Working Capital to Net Assets Ratio
CANBRIDGE PHARM.DL-00001 working capital to net assets ratio. CANBRIDGE PHARM.DL-00001 (MF1) has a Working Capital to Net Assets ratio of 101.0% as of December 2025. Working capital of €-345.17 Million (current assets of €110.17 Million minus current liabilities of €455.34 Million) is measured against net assets of €-341.75 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible net worth ratio of CANBRIDGE PHARM.DL-00001 to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of CANBRIDGE PHARM.DL-00001 (2021–2025)
Working capital to net assets ratio of CANBRIDGE PHARM.DL-00001 from 2021 to 2025. This chart shows how CANBRIDGE PHARM.DL-00001's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 101.0%, reflecting working capital of €-345.17 Million against net assets of €-341.75 Million EUR. See MF1 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
CANBRIDGE PHARM.DL-00001 Working Capital to Net Assets Ratio by Year (2021–2025)
CANBRIDGE PHARM.DL-00001 working capital to net assets ratio by year from 2021 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for CANBRIDGE PHARM.DL-00001 from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see MF1 total asset value.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 101.0% | €-345.17 Million | €-341.75 Million | €110.17 Million | €455.34 Million | ▲ +8.8 pp |
| 2024 | 92.2% | €-437.26 Million | €-474.49 Million | €45.35 Million | €482.61 Million | ▼ -204.6 pp |
| 2023 | 296.8% | €-118.08 Million | €-39.79 Million | €209.86 Million | €327.94 Million | ▲ +223.2 pp |
| 2022 | 73.6% | €227.06 Million | €308.56 Million | €505.16 Million | €278.11 Million | ▼ -16.7 pp |
| 2021 | 90.3% | €625.93 Million | €693.39 Million | €811.71 Million | €185.78 Million | — |